EyePoint Pharmaceuticals was listed on Nasdaq, accompanied by rating updates from TD Cowen (downgrade) and Jefferies (upgrade).

The entities involved

• EyePoint Pharmaceuticals (United Kingdom) →

  company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery

  • Trump's pledge to unleash American oil and gas benefits certain stocks, impacting EyePoint Pharmaceuticals.Sun 07:17
• Nasdaq →

  American fully electronic stock exchange

  • Apple Inc. stock is traded on Nasdaq, and Jefferies Financial Group restated a hold rating on the company.Mon 17:22
  • Vanguard Short-Term Inflation-Protected Securities ETF is disclosing its holdings to the SEC and trading on the Nasdaq electronic stock exchange.Mon 16:28
• TD Cowen →

  American investment bank

  • Analyst downgraded Ag Growth International Inc. due to debt management risks.Mon 12:33
  • TD Cowen raised its price target and gave a buy rating for Travere Therapeutics, Inc., while various institutional investors bought into the company.Mon 10:36

Related events

• TD Cowen increased its target price to $3.00, while Jefferies Financial Group was involved in a rating update for Plug Power, with MarketBeat aggregating the consensus data.Sep 4
• Ally Financial received a Strong Buy rating at $55 from Raymond James, while EyePoint Pharmaceuticals had its target slashed 80% to $4.Sep 2
• Analyst firms Jefferies and TD Cowen upgraded their ratings for Forgent Power Solutions, Inc., while MarketBeat provided consensus data.Sep 15
• Rating firms Raymond James Financial and TD Cowen provided reaffirmed buy ratings and price targets for a company listed on Nasdaq.Thu 23:04
• TD Cowen upgraded Crescent Biopharma shares to 'strong-buy', while Wedbush reiterated 'outperform', and a CEO sold shares under a 10b5-1 plan.Aug 27